HEALTHCARE

May 23, 2018

UN: violence in Libya having devastating impact on health care

Ongoing violence in Libya is having a devastating impact on health care, according to a Tuesday report [text] from the UN Human Rights Office and UN Support Mission in Libya (UNSMIL) [official website] studying the effects from May 1, 2017, to May 1, 2018. The report highlights the effects of crossfire between armed groups on hospitals and other medical facilities. Many times the crossfire has led to deaths, the destruction of key infrastructure and closures. According to the report: Medical facilities have been looted. Armed groups, including......

Read More >>

May 23, 2018

ResMed Studies Show Remote Monitoring and Automated Resupply Improve Adherence to PAP Therapy

(AETOS Wire)-- Remote patient monitoring and resupply programs have been shown to improve patient adherence to positive airway pressure (PAP) therapy, according to two separate studies presented by ResMed (NYSE: RMD, ASX: RMD) this week at the ATS"...

Read More >>

May 23, 2018

Spiolto® Respimat® enables greater physical activity in people living with Chronic Obstructive Pulmonary Disease  

  • Data presented at American Thoracic Society meeting underpin the benefits of Spiolto® Respimat® for physical activity in COPD1,2
  • Study published in American Journal of Respiratory and Critical Care Medicine shows Spiolto® Respimat® improves exercise capacity in COPD3
  • International GOLD 2018 Strategy recommends physical...

    Read More >>

May 22, 2018

Nearly 1 Billion People Worldwide Have Sleep Apnea, International Sleep Experts Estimate

(AETOS Wire) -- A new data analysis presented by ResMed (NYSE: RMD, ASX: RMD) this week at the ATS 2018 International Conference indicates that the prevalence of sleep apnea impacts more than 936 million people worldwide – nearly 10 times greater"...

Read More >>

May 22, 2018

Efficacy and safety of OFEV® reinforced in new presentations at ATS 2018

  • New analysis of the INPULSIS® and TOMORROW trials suggests treatment with OFEV® (nintedanib) associated with reduced risk of death in patients with idiopathic pulmonary fibrosis
  • Separate analysis of INPULSIS® trials showed association between lung function decline and worsening in health-related quality of life

May 21, 2018

Emirates Hospital Unveils Collaboration with the UAE’s Leading Rheumatology Specialist Humeira Badsha Medical Centre

The Humeira Badsha Medical Centre (HBMC), UAE's leading specialist in musculoskeletal diseases, announced it will be collaborating with Emirates Hospital, an Emirates Healthcare Company as it officially opened the doors of its new facility to the public in Emirates Hospital, Dubai.

"...

Read More >>

May 21, 2018

Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1

(AETOS Wire) -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted marketing authorisation for JULUCA® (dolutegravir 50mg [ViiV Healthcare]/rilpivirine 25mg [Janssen Sciences"...

Read More >>

May 21, 2018

ResMed-sponsored Studies Show Combining Home Oxygen and Home Non-invasive Ventilation is a Cost Effective Treatment for COPD

(AETOS Wire) -- ResMed (NYSE: RMD, ASX: RMD) announced today the results of two clinical analyses conducted for the U.K. and U.S., demonstrating the cost effectiveness of combining home oxygen therapy and home non-invasive ventilation (NIV) therapy"...

Read More >>

May 21, 2018

Julphar Wins Frost & Sullivan Best Practices Award

Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, has won the Frost & Sullivan 2018 Award for the Best Emerging GCC Pharma Company. The awards program, now in its fourth year, is based on Frost & Sullivan's research on best practices in growth, innovation and leadership and honors best-in-class innovators and disruptors from various industries in the region. Julphar was recognized for its strong overall performance and effective strategy. Rashid Khan, Julphar’s Regional Director (GCC......

Read More >>

May 20, 2018

Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings

(AETOS Wire) -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the company will feature a total of 14 Takeda Oncology-sponsored presentations at two upcoming medical meetings: the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5 in Chicago and the 23rd Congress of the European Hematology Association (EHA), June 14-17 in Stockholm. This year’s presentations will underscore Takeda’s unwavering pursuit to advance hematologic cancer therapy and continue building upon research in difficult-to-treat solid tumors. “At ASCO and EHA we will present data, real-world findings and......

Read More >>

Found articles: - Pages